Notes on Peptic Ulcers, Mucosal Defense, and NSAID Pharmacology

Overview of Peptic Ulcers

• Peptic ulcers occur when aggressive factors that break down gastric mucosal defenses overwhelm defensive factors, leading to mucosal injury and ulceration. The balance between aggression and defense can tilt toward ulceration if aggressive factors rise or defensive factors fall, or both.
• Major causes include:
  • Helicobacter pylori infection (the main cause; to be discussed in a separate session).
  • Nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Together, H. pylori and NSAIDs account for the vast majority of ulcers.
• Other, rarer or more idiopathic causes exist when neither major risk factor is found.
• Zollinger-Ellison Syndrome (ZES) is a rare but interesting cause: a gastrin-secreting tumor causing acid hypersecretion. Acid is required for ulcer formation—true in general—but acid alone rarely causes ulcers unless there is overwhelming gastric acid secretion as in ZES.
• The lecturer emphasizes that if clinicians encounter ZES, it is exceptionally rare but important to recognize; receptor of this syndrome is a gastrinoma leading to marked acid production.
• Traditional concept: acid is necessary for ulcer formation, but not sufficient on its own in most cases.

Definitions: Erosion vs Peptic Ulcer

• Erosion: a superficial mucosal break that does not extend beyond the muscularis mucosa.
• Ulcer: a break that extends through the mucosa and into the submucosa; depth is key.
• Size threshold for ulcers:
  • Typically greater than 3\,\text{mm}, sometimes defined as greater than 5\,\text{mm}.
• Anatomical context (gastric histology):
  • Lumen → mucosa → muscularis mucosa → submucosa → muscularis externa (the muscle layer) → serosa.
  • An erosion denudes only the mucosa (not beyond the muscularis mucosa).
  • An ulcer denudes the mucosa and extends into the submucosa, and in severe cases may reach deeper layers, potentially leading to gastric perforation if it traverses the entire gastric wall.

Mucosal Protection and Prostaglandins

• Endogenous prostaglandins are the most important factor in regulating gastric mucosal defenses.
• Concepts to know (historical terms): cytoprotection and adaptive cytoprotection. These terms described defense against noxious agents but are not used as commonly today.
• Mechanisms by which prostaglandins protect the mucosa:
  • Stimulate mucus secretion and bicarbonate secretion.
  • Critically maintain mucosal blood flow.
  • By maintaining blood flow, they preserve the proliferative zone in the gastric pits, supporting regeneration and repair.
• If mucosal blood flow falls, other protective mechanisms collapse and cells die.
• Conceptual schema: Prostaglandins promote mucus+gel, bicarbonate secretion, and blood flow to sustain regeneration and repair of the mucosa.

Prostaglandin Synthesis and the COX Family

• Prostaglandins are synthesized from membrane phospholipids; enzymes convert phospholipids to arachidonic acid, then cyclooxygenases (COX) convert to prostaglandins.
• COX enzymes are divided into two main classes:
  • COX-1: constitutively expressed throughout the body; involved in normal physiological functions including gastric mucosal protection.
  • COX-2: inducible and upregulated during inflammation; a target for anti-inflammatory therapy.
• The completeness of COX-1/COX-2 mapping underpins the rationale for NSAID therapy and its gastric toxicity.

NSAIDs, Prostaglandin Inhibition, and Gastric Mucosal Defense

• NSAIDs inhibit prostaglandin synthesis by inhibiting COX enzymes, thereby reducing gastric mucosal defenses and increasing ulcer risk.
• Mechanistic overview:
  • Non-selective NSAIDs inhibit both COX-1 and COX-2, reducing protective prostaglandins in the gastric mucosa.
  • This systemic effect, rather than a purely topical gastric exposure, explains why ulcers occur even with rectal administration; ulcers rates are similar whether NSAIDs are given orally or rectally.
• The presentation emphasizes that damage to the gastric mucosa from NSAIDs is largely systemic rather than confined to the stomach.
• COX-2 selective inhibitors aim to preserve gastric defenses while dampening inflammatory processes, but they are not without risk.
• Non-selective NSAIDs are effective for inflammatory arthritis and reduce ulcer incidence relative to non-selective agents only by lowering inflammation—not by eliminating risk; they typically reduce ulcer incidence by about half or more compared with traditional NSAIDs when COX-2 inhibitors are used.
• Practical note: Selective COX-2 inhibitors may delay ulcer healing and lack antiplatelet effects, which has cardiovascular implications.
• All NSAIDs can have cardiovascular, hypertension, and renal risks; early COX-2 inhibitors were withdrawn from the market due to safety concerns.

COX-2 Inhibitors versus Non-Selective NSAIDs: Benefits and Risks

• Selective COX-2 inhibitors (e.g., celecoxib):
  • Reduce inflammation with less gastric mucosal damage than non-selective NSAIDs.
  • Do not have antiplatelet effects that are cardioprotective, which can influence cardiovascular risk profile.
  • Associated with slightly increased cardiovascular risk in predisposed individuals (ischemia), hypertension, and renal impairment; risk appears dose-dependent.
  • Some early COX-2 inhibitors were withdrawn due to safety concerns; celecoxib is commonly used at lower doses to minimize risk.
• Non-selective NSAIDs (traditional NSAIDs):
  • Inhibit both COX-1 and COX-2; reduce inflammation but carry higher risk of gastric mucosal injury due to loss of protective prostaglandins.
  • Effect on platelets (e.g., aspirin) contributes to cardiovascular effects; COX-2 inhibitors lack these antiplatelet effects.
• Important historical note: Sir John Vane, English physiologist, helped establish that aspirin and NSAIDs inhibit prostaglandin synthesis; awarded the Nobel Prize in 1982.
• Visual evidence referenced: a scanning electron micrograph showing aspirin causes dose-dependent mucosal destruction when taken systemically; protective effect is much less at very low doses compared with higher doses.
• Cardiovascular considerations: COX-2 inhibitors may increase ischemic risk in susceptible individuals, and some COX-2 inhibitors have been associated with hypertension and renal issues; risk appears to be dose-dependent.
• Current clinical example: celecoxib is the COX-2 inhibitor most commonly used in practice, especially at lower doses to mitigate risks.

Aspirin and Dose-Dependent Mucosal Effects

• Aspirin, a traditional (non-selective) NSAID, causes gastric mucosal damage in a dose-dependent manner when taken systemically.
• Even though NSAID exposure may be systemic, the mucosal damage correlates with dose rather than the route of administration alone.
• The figure described (scanning electron micrograph) demonstrates that higher doses of aspirin produce more pronounced mucosal injury than low doses.
• At cardioprotective (low) doses, the mucosal destructive effect is significantly reduced compared with higher therapeutic doses.

Zollinger-Ellison Syndrome (Rare but Interesting Case)

• Zollinger-Ellison Syndrome is a very rare cause of peptic ulcers due to gastrin-secreting tumors (gastrinomas).
• It is characterized by acid hypersecretion; however, acid alone rarely causes ulcers unless there is overwhelming acid production as seen in ZES.
• The speaker emphasizes awareness of ZES as a rare but notable condition that can present with ulcers.

Key Takeaways for Clinical Relevance

• Most peptic ulcers are due to H. pylori infection and NSAID use; a minority are idiopathic.
• Acid is a necessary component in ulcer formation but not sufficient alone in most cases; its role becomes dominant in rare syndromes like ZES.
• Prostaglandins are central to gastric mucosal defense by promoting mucus, bicarbonate, and blood flow; disruption of prostaglandin synthesis by NSAIDs explains much of the ulcer risk.
• Distinguishing erosion from ulcer is clinically important: erosion is limited to mucosa; ulcers breach the mucosa and into submucosa, with potential deeper penetration.
• COX-1 vs COX-2 biology drives NSAID strategies: non-selective NSAIDs reduce protection and inflammation; COX-2 inhibitors reduce inflammation with less gastric injury but carry cardiovascular and renal risks; low-dose aspirin has distinct antiplatelet effects and cardioprotective considerations.
• Historical context: the discovery of prostaglandin synthesis inhibition by NSAIDs (and the Nobel Prize awarded to Sir John Vane) underpins current therapeutic approaches.

Connections to Foundations and Real-World Relevance

• The discussion connects mucosal defense mechanisms with everyday pharmacology, especially NSAID prescribing patterns for inflammatory diseases.
• It highlights the trade-offs between anti-inflammatory efficacy and gastric safety, informing decisions about using COX-2 selective inhibitors or gastroprotective strategies in high-risk patients.
• The material integrates anatomy (gastric wall layers), physiology (blood flow and regeneration in the gastric mucosa), and pharmacology (prostaglandin pathways and NSAID effects) to explain ulcer pathogenesis and prevention approaches.